Recombinant Shigella flexneri ipaC Protein ，His & Myc

The study of ipaC recombinant protein is rooted in the field of microbiology and immunology, particularly in the context of understanding the pathogenic mechanisms of enteropathogenic bacteria such as Shigella flexneri. IpaC is a key effector protein secreted by the type III secretion system (T3SS), playing a critical role in bacterial invasion and manipulation of host cell signaling pathways. Research into ipaC has garnered interest due to its potential as a target for vaccine development and therapeutic interventions against shigellosis, a significant public health concern in many developing countries. Characterization of ipaC's structure and function is essential for elucidating its role in the bacterial lifecycle and host-pathogen interactions. Studies utilizing recombinant technology have enabled the production of ipaC in sufficient quantities for functional assays and immunogenicity testing, thereby advancing our understanding of its biochemical properties and potential applications in vaccines. By exploring the immunological responses elicited by ipaC in animal models, researchers aim to establish its efficacy as a candidate for protective vaccines, which could significantly reduce the incidence of infections caused by Shigella spp. and similar pathogens. Overall, ongoing research into ipaC recombinant protein not only enhances our comprehension of bacterial pathogenesis but also contributes to the development of innovative strategies to combat infectious diseases.